Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Ciccolini

Showing results (101-110 of 168) with videos related to

Pageof 17
Sort By:
Critical Reviews in Oncology/Hematology|May 29, 2024
Tyrosine kinase inhibitors in cancers: Treatment optimization - Part IIFlorent Ferrer, Pauline Tetu, Léa Dousset, et al.
Critical Reviews in Oncology/Hematology|May 18, 2024
Tyrosine kinase inhibitors in cancers: Treatment optimization - Part IDavid Combarel, Léa Dousset, Stéphane Bouchet, et al.
The British Journal of Radiology|April 5, 2016
An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept studyLaetitia Padovani, Aurelie Baret, Joseph Ciccolini, et al.
Anti-Cancer Drugs|March 22, 2006
Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro studyRaphaelle Fanciullino, Alexandre Evrard, Pierre Cuq, et al.
Fundamental & Clinical Pharmacology|June 1, 2011
Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinantsMohamed Chefrour, Gérard Milano, Patricia Formento, et al.
Pharmacogenomics|July 11, 2013
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimenCindy Serdjebi, Jean-François Seitz, Joseph Ciccolini, et al.
Therapeutic Drug Monitoring|March 19, 2019
Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future OpportunitiesGareth J Veal, Edward B Amankwatia, Marie-Noëlle Paludetto, et al.
British Journal of Clinical Pharmacology|September 23, 2015
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancerManon Launay, Laetitia Dahan, Manon Duval, et al.
Biomarker Insights|September 1, 2016
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision MedicineAdel Gouri, Aoulia Dekaken, Khalid El Bairi, et al.
Pharmacogenomics|June 11, 2013
Personalized medicine in oncology: where have we come from and where are we going?Fabrice André, Joseph Ciccolini, Jean-Philippe Spano, et al.
Pageof 17

Showing results (101-110 of 168) with videos related to

Sort By:
Pageof 17
Critical Reviews in Oncology/Hematology|May 29, 2024
Tyrosine kinase inhibitors in cancers: Treatment optimization - Part IIFlorent Ferrer, Pauline Tetu, Léa Dousset, et al.
Critical Reviews in Oncology/Hematology|May 18, 2024
Tyrosine kinase inhibitors in cancers: Treatment optimization - Part IDavid Combarel, Léa Dousset, Stéphane Bouchet, et al.
The British Journal of Radiology|April 5, 2016
An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept studyLaetitia Padovani, Aurelie Baret, Joseph Ciccolini, et al.
Anti-Cancer Drugs|March 22, 2006
Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro studyRaphaelle Fanciullino, Alexandre Evrard, Pierre Cuq, et al.
Fundamental & Clinical Pharmacology|June 1, 2011
Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinantsMohamed Chefrour, Gérard Milano, Patricia Formento, et al.
Pharmacogenomics|July 11, 2013
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimenCindy Serdjebi, Jean-François Seitz, Joseph Ciccolini, et al.
Therapeutic Drug Monitoring|March 19, 2019
Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future OpportunitiesGareth J Veal, Edward B Amankwatia, Marie-Noëlle Paludetto, et al.
British Journal of Clinical Pharmacology|September 23, 2015
Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancerManon Launay, Laetitia Dahan, Manon Duval, et al.
Biomarker Insights|September 1, 2016
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision MedicineAdel Gouri, Aoulia Dekaken, Khalid El Bairi, et al.
Pharmacogenomics|June 11, 2013
Personalized medicine in oncology: where have we come from and where are we going?Fabrice André, Joseph Ciccolini, Jean-Philippe Spano, et al.
Pageof 17